Telmisartan, which is an ARB with PPAR-regulating activity, was compared to the use of valsartan in the fatty liver protection by telmisartan (FANTASY) trial and found to cause a reduction in necroinflammation, NAFLD activity score (NAS) and fibrosis stage in NASH, as well as microalbuminuria [95]. Here, PPARA is linked to metabolic dysfunction-associated steatotic liver disease.